Method for evaluating prediction models that apply the results of randomized trials to individual patients

Trials

Volumn 8, Issue , 2007, Pages

  Vickers, Andrew J ^a   Kattan, Michael W ^b   Daniel, Sargent ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DUTASTERIDE; LEVAMISOLE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CLINICAL RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; COLORECTAL SURGERY; DEATH; HUMAN; INTERMETHOD COMPARISON; MEDICAL DECISION MAKING; PREDICTION; PROSTATE HYPERTROPHY; RISK REDUCTION; TREATMENT OUTCOME;

EID: 34447646946     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-8-14     Document Type: Article

References (25)

1. Gill S Loprinzi CL Sargent DJ Thome SD Alberts SR Haller DG Benedetti J Francini G Shepherd LE Francois SJ Labianca R Chen W Cha SS Heldebrant MP Goldberg RM Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 2004 22 1797-1806 10.1200/JCO.2004.09.059 15067028
2. Loprinzi CL Thome SD Understanding the utility of adjuvant systemic therapy for primary breast cancer J Clin Oncol 2001 19 972-979 11181659
3. Kent DM Hayward RA Griffith JL Vijan S Beshansky JR Califf RM Selker HP An independently derived and validated predictive model for selecting patients with myocardial infarction who are likely to benefit from tissue plasminogen activator compared with streptokinase Am J Med 2002 113 104-111 10.1016/S0002-9343(02)01160-9 12133748
4. Rothwell PM Warlow CP Prediction of benefit from carotid endarterectomy in individual patients: A risk-modelling study. European Carotid Surgery Trialists' Collaborative Group Lancet 1999 353 2105-2110 10.1016/ S0140-6736(98)11415-0 10382694
5. 2006 http://www.mskcc.org/nomograms Accessed July 20
6. 2006 http://www.adjuvantonline.com Accessed July 20
7. 2006 http://www.mayoclinic.com/calcs/ Accessed July 20
8. Sonpavde G Communicating the value of adjuvant chemotherapy J Clin Oncol 2003 21 948-949 10.1200/JCO.2003.09.074 12610199
9. Rothwell PM Can overall results of clinical trials be applied to all patients? Lancet 1995 345 1616-1619 10.1016/S0140-6736(95)90120-5 7783541
10. Glasziou PP Irwig LM An evidence based approach to individualising treatment BMJ 1995 311 1356-1359 7496291
11. Sox H Blatt M Marton K Medical Decision Making. Stoneham, MA, Butterworth Publishers 1988
12. Harrell FE Jr. Califf RM Pryor DB Lee KL Rosati RA Evaluating the yield of medical tests JAMA 1982 247 2543-2546 10.1001/jama.247.18.2543 7069920
13. Vickers AJ Elkin EB Decision curve analysis: A novel method for evaluating prediction models Medical Decision Making 2006 26 565-574 10.1177/0272989X06295361 17099194
14. Moertel CG Fleming TR Macdonald JS Haller DG Laurie JA Tangen CM Ungerleider JS Emerson WA Tormey DC Glick JH Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer J Clin Oncol 1995 13 2936-2943 8523058
15. 2006 http://www.mayo.edu/hsr/people/therneau/book/data/colon.html Accessed July 20
16. McConnell JD Bruskewitz R Walsh P Andriole G Lieber M Holtgrewe HL Albertsen P Roehrborn CG Nickel JC Wang DZ Taylor AM Waldstreicher J The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group N Engl J Med 1998 338 557-563 10.1056/NEJM199802263380901 9475762
17. Wasson JH Finasteride to prevent morbidity from benign prostatic hyperplasia N Engl J Med 1998 338 612-613 10.1056/NEJM199802263380909 9475770
18. Roehrborn CG Boyle P Nickel JC Hoefner K Andriole G Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia Urology 2002 60 434-441 10.1016/ S0090-4295(02)01905-2 12350480
19. Slawin KM Kattan MW Roehrborn CG Wilson T Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia Urology 2006 67 84-88 10.1016/j.urology.2005.07.013 16413338
20. Jansen SJ Kievit J Nooij MA de Haes JC Overpelt IM van Slooten H Maartense E Stiggelbout AM Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: Is treatment worthwhile? Br J Cancer 2001 84 1577-1585 10.1054/bjoc.2001.1836 11401308
21. MRC Streptomycin in Tuberculosis Trials Committee Streptomycin treatment of pulmonary tuberculosis British Medical Journal 1948 769-783
22. Andre T Boni C Mounedji-Boudiaf L Navarro M Tabernero J Hickish T Topham C Zaninelli M Clingan P Bridgewater J Tabah-Fisch I De Gramont A Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer N Engl J Med 2004 350 2343-2351 10.1056/NEJMoa032709 15175436
23. Cristofanilli M Budd GT Ellis MJ Stopeck A Matera J Miller MC Reuben JM Doyle GV Allard WJ Terstappen LWMM Hayes DF Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer The New England Journal of Medicine 2004 351 781-791 10.1056/NEJMoa040766 15317891
24. Braun S Marth C Circulating Tumor Cells in Metastatic Breast Cancer -- Toward Individualized Treatment? The New England Journal of Medicine 2004 351 824-826 10.1056/NEJMe048163 15317898
25. Lippman SM Levin B Brenner DE Gordon GB Aldige CR Kramer BS Garber JE Hawk E Ganz PA Somerfield MR Cancer Prevention and the American Society of Clinical Oncology Journal of Clinical Oncology 2004 22 3848-3851 10.1200/JCO.2004.07.139 15353541